|Description||This active molecular is a hepatoselective glucokinase activator that reduces MDG (mean daily glucose), FPG (fasting plasma glucose) and glucose excursion in humans. PF-04991532 may offer glycemic control without inducing hepatic steatosis. PF-04991532 was developed by Pfizer but was discontinued in Phase-II for Type-2 diabetes mellitus in USA in 2012.|
|Appearance||White to beige powder|
|Synonyms||PF-04991532; PF 04991532; PF04991532; PF-4991532; PF4991532; PF 4991532; UNII-AJ212MS2O2; CHEMBL2165620; AJ212MS2O2; SCHEMBL1711504; BDBM50394681; 6-[[(2S)-3-cyclopentyl-2-[4-(trifluoromethyl)imidazol-1-yl]propanoyl]amino]pyridine-3-carboxylic acid|
|Solubility||Soluble in DMSO|
|Application||Type 2 diabetes mellitus|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator: Pfizer|
RO 28-1674 is a glucokinase GK agonist.
LBX192 is a Liver Targeted Glucokinase Activator. It can activate the GK enzyme in vitro at low nM concentrations and reduce glucose levels during an oral gluco...
A cell-permeable thiazolyl-propanamide compound that acts as a glucokinase (GK) activator by increasing Vmax and decreasing [S]1/2 of GK-catalyzed reaction as w...
ARRY-403 is an orally available Glucokinase stimulants originated by Array BioPharma. ARRY-403 activates human glucokinase in vitro with EC50 of 79 nM at 5 mM g...
GKA 50 is a potent glucokinase activator (EC50 = 33 nM). It causes a decrease in plasma glucose levels in diabetic rats and an increase of insulin release from ...
LY2608204 activates glucokinase (GK) with EC50 of 42 nM at 10 mM glucose with a concentration dependent manner at lower glucose concentrations.
This active molecular is a hepatoselective glucokinase activator that reduces MDG (mean daily glucose), FPG (fasting plasma glucose) and glucose excursion in hu...
AM-9514 is a glucokinase (GK) activator. It shows a favorable combination of in vitro potency, enzyme kinetic properties, acceptable pharmacokinetic profiles in...